inne is a Berlin-based FemHealth, Scale Up 6th Cohort company revolutionizing women’s health by providing a more accurate and convenient way to track fertility. Combining biochemistry and technology, inne’s 30-second at-home saliva test measures progesterone levels to predict and confirm ovulation, offering deeper insights than traditional tracking apps. To compliment their device, Inne created an app that helps users understand what their test results mean and how they affect everyday fertility. Their mission is to empower women to tune into their bodies, make informed decisions about their reproductive health, and take control of their fertility with a seamless, science-backed solution.

Inne raised $10 million in Series A funding, led by DSM Venturing with participation from Borski Fund, Calm Storm Ventures, and notable angels including Taavet Hinrikus (Wise), Dr. Fiona Pathiraja, and Rolf Schromgens (Trivago). The funding will support Inne’s continued development of its minilab and platform, enabling expansion into new areas of women’s health and entry into the U.S. market.

Inne is Three:

What problem is Inne solving? inne solves the problem of unreliable and inconvenient fertility tracking by offering a precise, easy-to-use solution that measures hormone levels daily.

What’s innovative about Inne? inne’s innovation lies in its 30-second at-home saliva biosensor that tracks progesterone levels and predicts ovulation, combined with an app that interprets the data.

Who can use Inne? Women seeking accurate, natural fertility tracking for contraception or family planning can use inne's solution.

The company is not only revolutionizing how women track and understand their hormonal health, but has also received the backing of notable VCs and entities including DSM, Borski Fund and Blossom Capital, as well as high-profile angel investors, including Trivago founder Rolf Schroemgens.